Skip to content

Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster

Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster: A Prospective Comparative Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06476080
Enrollment
120
Registered
2024-06-26
Start date
2024-07-05
Completion date
2025-04-15
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Herpes Zoster Neuropathy

Brief summary

Acute herpes zoster pain is very severe . Conventional analgesics may be of no value. Regional blocks may play a role

Interventions

PROCEDUREultrasound guided erector spine block

Ultrasound guided thoracic erector spinae block

Ultrasound guided serratus anterior block

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adult population between 30 and 75 years old. * Unilateral painful thoracic herpetic eruption of less than one week duration. * VAS more than or equal 4, persistent pain in spite of proper antiviral and analgesic therapy, (800 mg oral acyclovir, 5 times per day, for one week), pregabalin 300 mg per day, acetaminophen 1000 mg per day, topical calamine lotion).

Exclusion criteria

* Diabetic patients. * Painful herpetic eruptive vesicles more than one week. * Abdominal herpetic eruptions. * Non-compliant on anti-viral (bulbar palsy for example). * Co-malignancy or radiotherapy. * Steroid therapy \> 5 mg prednisolone or its equivalent. * Infections or hematoma at site of injection. * Coagulopathy (chronic kidney or liver disease, clopidogrel use).

Design outcomes

Primary

MeasureTime frameDescription
pain scoreimmediate after injection, 1 week, 1, 3 monthsVisual analogue scale from 0 to 10. 0= NO pain, 1-3=mild tolerable pain, 4-6= moderate pain, 7-10= severe untearable pain.

Secondary

MeasureTime frameDescription
Incidence of treatment related adverse eventsimmediately after injectionhypotension, bradyarrhythmia, hematoma
Number of patients with pain recurrence1 week, 1, and 3 monthsNumber of patients in need for re-injection
analgesic consumption1 week, 1, and 3 monthstotal amount dose of analgesics used

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026